公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Takeshi YASUI ,  Keiko KAKEGAWA ,  Zenichi IKEDA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Akinori TOITA ,  Takuto KOJIMA ,  Yasutomi ASANO ,  Ayumu SATO ,  Hironobu MAEZAKI ,  Shinobu SASAKI ,  Hironori KOKUBO ,  Misaki HOMMA ,  Minoru SASAKI ,  Yasuhiro IMAEDA

IPC: C07D413/14 ,  C07D471/04 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20200255439A1

公开(公告)日：2020-08-13

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto KAMATA ,  Hideyuki SUGIYAMA ,  Minoru NAKAMURA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Tomohiro OKAWA ,  Hidekazu TOKUHARA

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20240390508A1

公开(公告)日：2024-11-28

申请号：US18685457

申请日：2022-08-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takatoshi YOGO ,  Hideyuki SUGIYAMA ,  Kenichi MIYATA ,  Hiroyuki TAKADA ,  Masato YOSHIDA ,  Ryosuke TOKUNOH ,  Yasuo NAKAGAWA ,  Masato NIWA ,  Shigekazu SASAKI ,  Masaki OHUCHI ,  Naoki SAWAI ,  Masatoshi TAKUWA ,  Yujiro UCHINO ,  Yoko KANEMATSU ,  Koichiro FUKUDA ,  Takanori YOKOTO ,  Tetsuya NAGATA ,  Hiroki YAMADA

IPC: A61K47/64 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

Abstract: The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

公开(公告)号：US20210094944A1

公开(公告)日：2021-04-01

申请号：US17030504

申请日：2020-09-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  C07D413/10 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20180079756A1

公开(公告)日：2018-03-22

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Tatsuki KOIKE ,  Jumpei AIDA ,  Makoto FUSHIMI ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Masako MIYAZAKI ,  Hidekazu TOKUHARA ,  Yasushi HATTORI ,  Makoto KAMATA

IPC: C07D498/04 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D498/04 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D401/06 ,  C07D401/10 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C12N9/99

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170283406A1

公开(公告)日：2017-10-05

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: C07D413/14 ,  C07D413/08 ,  C07D405/14 ,  C07D401/08

CPC classification number: C07D413/14 ,  C07D401/06 ,  C07D401/08 ,  C07D405/14 ,  C07D413/06 ,  C07D413/08

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20240343721A1

公开(公告)日：2024-10-17

申请号：US18635839

申请日：2024-04-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20190125728A1

公开(公告)日：2019-05-02

申请号：US16089548

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei IKEDA ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: A61K31/4188 ,  A61K31/407 ,  A61K31/454 ,  A61K31/496 ,  A61P25/16 ,  A61P25/08 ,  A61P25/24 ,  A61P25/28 ,  A61P21/00

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20230183227A1

公开(公告)日：2023-06-15

申请号：US17952546

申请日：2022-09-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I)




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20220098180A1

公开(公告)日：2022-03-31

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Hideyuki SUGIYAMA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Osamu KUBO ,  Akinori TOITA ,  Takuto KOJIMA ,  Fumiaki KIKUCHI ,  Minoru SASAKI ,  Misaki HOMMA ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Shiinobu SASAKI ,  Ayumu SATO ,  Hirotaka KAMITANI ,  Yasutomi ASANO ,  Hironori KOKUBO ,  Masato YOSHIKAWA

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.